Russell Investments Group
ADCT icon

Russell Investments Group’s ADC Therapeutics ADCT Stock Holding History

Russell Investments Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$956K Buy
254,909
+230,377
+939% +$908K ﹤0.01% 2233
2025
Q4 		$86.6K Sell
24,532
-7,970
-25% -$32.3K ﹤0.01% 3093
2025
Q3 		$130K Buy
32,502
+7,701
+31% +$24.3K ﹤0.01% 2950
2025
Q2 		$66.5K Sell
24,801
-14,887
-38% -$31.3K ﹤0.01% 2917
2025
Q1 		$56K Buy
39,688
+22,894
+136% +$38.9K ﹤0.01% 2885
2024
Q4 		$33.4K Buy
16,794
+9,248
+123% +$24.2K ﹤0.01% 2913
2024
Q3 		$23.8K Buy
+7,546
New +$23.8K ﹤0.01% 2925
2023
Q1 		– Sell
-17,800
Closed -$68.4K – 3284
2022
Q4 		$68.4K Buy
+17,800
New +$71.2K ﹤0.01% 2713

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Russell Investments Group's ADCT Position: Q1 2026 in Review

Russell Investments Group increased its ADC Therapeutics (ADCT) stake by 939% in Q1 2026, buying an estimated $908K and bringing the position to 254,909 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #2233.

Russell Investments Group first reported a position in ADCT in Q4 2022 and has held it in 8 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Russell Investments Group held 254,909 shares of ADC Therapeutics worth $956K as of Q1 2026.
  • Russell Investments Group bought 230,377 ADC Therapeutics shares in Q1 2026, an estimated $908K.
  • ADC Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2233 holding.
  • Russell Investments Group first reported a position in ADC Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.